Press Releases Elicera Therapeutics AB

Equities

ELIC

SE0015382080

Delayed Nasdaq Stockholm Other stock markets 05:30:01 26/06/2024 pm IST			5-day change	1st Jan Change
1.445 ^SEK	-2.36%		+5.09%	-68.31%

11/06	Elicera Therapeutics Enters A Preclinical Collaboration Agreement with China Medical University for the Development of Elc-201	CI
29/05	Elicera Therapeutics Set to Begin First Clinical CAR T-Cell study CARMA	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

BioStock: Elicera teams up with China Medical University for cancer study	17/06	AQ
BioStock: Elicera's first clinical CAR T-Cell study CARMA set to begin	29/05	AQ
Elicera Therapeutics AB (publ) Interim Report 1 January - 31 March 2024	27/05	AQ
Elicera Therapeutics publishes the annual report for 2023	16/04	AQ
Nomination committee proposes CMC specialist to Elicera's board of directors	28/03	AQ
Elicera Therapeutics changes Certified Adviser and Liquidity provider to Mangold Fondkommission AB	22/03	AQ
Elicera Therapeutics announces outcome in rights issue	11/03	AQ
BioStock: Elicera collaborates with US cancer centre to evaluate iTANK	07/03	AQ
Elicera enters agreement with prominent US Cancer Center to evaluate the use of iTANK in T-cell receptor therapies	06/03	AQ
Elicera Therapeutics receives additional subscription commitments from the board and management in the ongoing rights issue	04/03	AQ
The subscription period in Elicera Therapeutics' rights issue of units starts today	23/02	AQ
Elicera Therapeutics publishes prospectus in connection with rights issue of units	21/02	AQ
BioStock: Full speed ahead for Elicera in 2024	19/02	AQ
Elicera Therapeutics' abstract on the iTANK platform's potential to enhance CAR T-cell treatment of solid tumors accepted for presentation at ISCT 2024	16/02	AQ
Elicera invites to investor meetings on February 28[th] and 29[th] 2024	16/02	AQ
BioStock: Elicera gets green light for CAR T clinical study	14/02	AQ
Elicera Therapeutics AB (publ) Year-End Report 1 January - 31 December 2023	13/02	AQ
Elicera Therapeutics receives approval to initiate clinical Phase I/II-study CARMA with CAR T-cell therapy ELC-301 in B-Cell lymphoma	09/02	AQ
NOTICE OF EXTRAORDINARY GENERAL MEETING IN elicera therapeutics AB	18/01	AQ
Elicera's Board of Directors proposes a rights issue of units of approximately SEK 64 million	18/01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Elicera Therapeutics AB

Equities

ELIC

SE0015382080

Press Releases

Filters